3 research outputs found
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
Background: Information about the adherence to scientific societies guidelines in the ‘real-world’ therapeutic
management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the
knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM).
Patients and methods: Treatment-naive adult patients with pancreatic adenocarcinoma were enrolled. Group A
received adjuvant therapy, group B received primary chemotherapy, and group C had metastatic disease. The results
on patients accrued until 31 October 2019 with a mature follow-up were presented.
Results: Since July 2017, 833 eligible patients of 923 (90%) were enrolled in 44 Italian centers. The median age was 69
years (range 36-89 years; 24% >75 years); 48% were female; 93% had Eastern Cooperative Oncology Group (ECOG)
performance status (PS) score of 0 or 1; group A: 16%, group B: 30%; group C: 54%; 72% Nord, 13% Center, 15%
South. In group A, guidelines adherence was 68% [95% confidence interval (CI) 59% to 76%]; 53% of patients
received gemcitabine and 15% gemcitabine þ capecitabine; median CA19.9 was 29 (range 0-7300; not reported
15%); median survival was 36.4 months (95% CI 27.5-47.3 months). In group B, guidelines adherence was 96% (95%
CI 92% to 98%); 55% of patients received nab-paclitaxel þ gemcitabine, 27% FOLFIRINOX, 12% gemcitabine, and 3%
clinical trial; median CA19.9 was 337 (range 0-20220; not reported 9%); median survival was 18.1 months (95% CI
15.6-19.9 months). In group C, guidelines adherence was 96% (95% CI 94% to 98%); 71% of patients received nabpaclitaxel þ gemcitabine, 16% gemcitabine, 8% FOLFIRINOX, and 4% clinical trial; liver and lung metastases were
reported in 76% and 23% of patients, respectively; median CA19.9 value was 760 (range 0-1374500; not reported
9%); median survival was 10.0 months (95% CI 9.1-11.1 months).
Conclusions: The GARIBALDI survey shows a very high rate of adherence to guidelines and survival outcome in line with
the literature. CA19.9 testing should be enhanced; nutritional and psychological counseling represent an unmet need.
Enrollment to assess adherence to updated AIOM guidelines is ongoing
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study
Pros-IT CNR : an Italian prostate cancer monitoring project
Aims: The Pros-IT CNR project aims to monitor a sample of Italian males 6518 years of age who have been diagnosed in the participating centers with incident prostate cancer, by analyzing their clinical features, treatment protocols and outcome results in relation to quality of life. Methods: Pros-IT CNR is an observational, prospective, multicenter study. The National Research Council (CNR), Neuroscience Institute, Aging Branch (Padua) is the promoting center. Ninety-seven Italian centers located throughout Italy were involved. The field study began in September 1, 2014. Subjects eligible were diagnosed with biopsy-verified prostate cancer, na\uefve. A sample size of 1500 patients was contemplated. A baseline assessment including anamnestic data, clinical history, risk factors, the initial diagnosis, cancer staging information and quality of life (Italian UCLA Prostate Cancer Index; SF-12 Scale) was completed. Six months after the initial diagnosis, a second assessment evaluating the patient\u2019s health status, the treatment carried out, and the quality of life will be made. A third assessment, evaluating the treatment follow-up and the quality of life, will be made 12 months after the initial diagnosis. The 4th, 5th, 6th and 7th assessments, similar to the third, will be completed 24, 36, 48 and 60 months after the initial diagnosis, respectively, and will include also a Food Frequency Questionnaire and the Physical Activity Scale for the Elderly. Discussion: The study will provide information on patients\u2019 quality of life and its variations over time in relation to the treatments received for the prostate cancer